{"id":510752,"date":"2021-07-08T07:03:51","date_gmt":"2021-07-08T11:03:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/"},"modified":"2021-07-08T07:03:51","modified_gmt":"2021-07-08T11:03:51","slug":"logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/","title":{"rendered":"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">LEXINGTON, Mass.<\/span>, <span class=\"xn-chron\">July 8, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0LogicBio Therapeutics, Inc.\u00a0(Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that <span class=\"xn-person\">Frederic Chereau<\/span>, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled &#8220;<i>Delivery and Durability of Genetic Medicines<\/i>&#8221; at the William Blair Biotech Focus Conference 2021 on <span class=\"xn-chron\">Thursday, July 15, 2021<\/span> at <span class=\"xn-chron\">10:00 a.m. ET<\/span>.<\/p>\n<p>\n        <b>About\u00a0LogicBio Therapeutics\u00a0<br \/><\/b>LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company&#8217;s first platform, GeneRide\u2122, is a new approach to precise gene insertion harnessing a cell&#8217;s natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company&#8217;s second platform, sAAVy\u2122, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in <span class=\"xn-location\">Lexington, MA.<\/span> For more information, visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3220066-1&amp;h=1009784103&amp;u=http%3A%2F%2Fwww.logicbio.com%2F&amp;a=www.logicbio.com\" rel=\"nofollow noopener\">www.logicbio.com<\/a>, which does not form a part of this release.<\/p>\n<p>\n        <b>Investor Contact<\/b>:\u00a0 <br \/><span class=\"xn-person\">Laurence Watts<\/span><br \/>Gilmartin Group <br \/>(619) 916-7620<br \/><a target=\"_blank\" href=\"mailto:laurence@gilmartinir.com\" rel=\"nofollow noopener\">laurence@gilmartinir.com<\/a><\/p>\n<p>\n        <b>Media Contacts:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Adam Daley<\/span><br \/>\n        <br \/>Berry &amp; Company Public Relations<br \/>W: 212-253-8881<br \/>C: 614-580-2048<br \/><a target=\"_blank\" href=\"mailto:adaley@berrypr.com\" rel=\"nofollow noopener\">adaley@berrypr.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Jenna Urban<\/span><br \/>\n        <br \/>Berry &amp; Company Public Relations<br \/>W: 212-253-8881<br \/>C: 203-218-9180<br \/><a target=\"_blank\" href=\"mailto:jurban@berrypr.com\" rel=\"nofollow noopener\">jurban@berrypr.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY35139&amp;sd=2021-07-08\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021-301327648.html\">https:\/\/www.prnewswire.com\/news-releases\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021-301327648.html<\/a><\/p>\n<p>SOURCE  LogicBio Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY35139&amp;Transmission_Id=202107080700PR_NEWS_USPR_____NY35139&amp;DateId=20210708\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire LEXINGTON, Mass., July 8, 2021 \/PRNewswire\/ &#8212;\u00a0LogicBio Therapeutics, Inc.\u00a0(Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled &#8220;Delivery and Durability of Genetic Medicines&#8221; at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET. About\u00a0LogicBio Therapeutics\u00a0LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company&#8217;s first platform, GeneRide\u2122, is a new approach to precise gene insertion harnessing a cell&#8217;s natural DNA repair process &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510752","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LEXINGTON, Mass., July 8, 2021 \/PRNewswire\/ &#8212;\u00a0LogicBio Therapeutics, Inc.\u00a0(Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled &#8220;Delivery and Durability of Genetic Medicines&#8221; at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET. About\u00a0LogicBio Therapeutics\u00a0LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company&#8217;s first platform, GeneRide\u2122, is a new approach to precise gene insertion harnessing a cell&#8217;s natural DNA repair process &hellip; Continue reading &quot;LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-08T11:03:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY35139&amp;sd=2021-07-08\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021\",\"datePublished\":\"2021-07-08T11:03:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/\"},\"wordCount\":249,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY35139&amp;sd=2021-07-08\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/\",\"name\":\"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY35139&amp;sd=2021-07-08\",\"datePublished\":\"2021-07-08T11:03:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY35139&amp;sd=2021-07-08\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY35139&amp;sd=2021-07-08\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 - Market Newsdesk","og_description":"PR Newswire LEXINGTON, Mass., July 8, 2021 \/PRNewswire\/ &#8212;\u00a0LogicBio Therapeutics, Inc.\u00a0(Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled &#8220;Delivery and Durability of Genetic Medicines&#8221; at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET. About\u00a0LogicBio Therapeutics\u00a0LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company&#8217;s first platform, GeneRide\u2122, is a new approach to precise gene insertion harnessing a cell&#8217;s natural DNA repair process &hellip; Continue reading \"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-08T11:03:51+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY35139&amp;sd=2021-07-08","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021","datePublished":"2021-07-08T11:03:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/"},"wordCount":249,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY35139&amp;sd=2021-07-08","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/","name":"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY35139&amp;sd=2021-07-08","datePublished":"2021-07-08T11:03:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY35139&amp;sd=2021-07-08","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY35139&amp;sd=2021-07-08"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510752"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510752\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}